دورية أكاديمية
Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib
| العنوان: | Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib |
|---|---|
| المؤلفون: | Ya‐Wen Hsiao, Fai‐Meng Sou, Jing‐Houng Wang, Yen‐Hao Chen, Ming‐Chao Tsai, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo |
| المصدر: | Kaohsiung Journal of Medical Sciences, Vol 39, Iss 12, Pp 1233-1242 (2023) |
| بيانات النشر: | Wiley, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine (General) |
| مصطلحات موضوعية: | hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, lenvatinib, well‐controlled viremia, Medicine (General), R5-920 |
| الوصف: | Abstract Lenvatinib has been approved as one of the first‐line treatments for advanced hepatocellular carcinoma (HCC) due to its high treatment efficacy being non‐inferior to sorafenib. Previous studies have shown well‐controlled viremia contributes to the prognosis of HCC patients receiving first‐line sorafenib; hence, we postulated this association might also exist in HCC patients with lenvatinib treatment. From April 2018 to December 2021, 201 unresectable HCC patients with first‐line lenvatinib treatment in our institute were assessed. High‐effect nucleoside analogues were administered for hepatitis B virus (HBV) control, while direct‐acting antivirals were used for hepatitis C virus (HCV) elimination. Based on our previous study, well‐controlled viremia was defined as patients who had undetectable viremia, or who had been receiving antivirals at least 6 months before lenvatinib. This study enrolled 129 patients, including 85 patients with HBV‐related HCC (HBV‐HCC) and 44 patients with HCV‐related HCC (HCV‐HCC), respectively. Progression‐free survival (PFS) and overall survival (OS) rates between the two groups were not different. Before administration of lenvatinib, 57.1% of the HBV‐HCC patients and 88.4% of the HCV‐HCC patients had well‐controlled viremia, and their PFS (8.8 vs. 3.1 months, p |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2410-8650 1607-551X |
| العلاقة: | https://doaj.org/toc/1607-551XTest; https://doaj.org/toc/2410-8650Test |
| DOI: | 10.1002/kjm2.12757 |
| الوصول الحر: | https://doaj.org/article/b1252245566d40eeb3fd8e2ddd0e4a28Test |
| رقم الانضمام: | edsdoj.b1252245566d40eeb3fd8e2ddd0e4a28 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24108650 1607551X |
|---|---|
| DOI: | 10.1002/kjm2.12757 |